NDATOPICALGEL
Approved
Jan 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
AVITA (tretinoin) by Pfizer is (rar) nuclear receptors (rarα, rarβ, and rarγ) which may act to modify gene expression, subsequent protein synthesis, and epithelial cell growth and differentiation, it has not been established whether the clinical effects of tretinoin are mediated through activation of retinoic acid receptors and/or other mechanisms. Approved for retinoid [epc]. First approved in 1998.
Drug data last refreshed 11h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AVITA is a topical retinoid gel containing tretinoin, a vitamin A derivative used to treat acne and photoaged skin. It works by activating retinoic acid receptors (RARα, RARβ, RARγ) to modify gene expression and epithelial cell differentiation. The mechanism decreases follicular cohesiveness, reduces microcomedone formation, and stimulates cellular turnover to extrude comedones.
LOE Approaching
AVITA faces approaching loss of exclusivity in a crowded generic and branded retinoid market, signaling contraction of brand-specific commercial roles.
Mechanism of Action
(RAR) nuclear receptors (RARα, RARβ, and RARγ) which may act to modify gene expression, subsequent protein synthesis, and epithelial cell growth and differentiation, it has not been established whether the clinical effects of tretinoin are mediated through activation of retinoic acid receptors…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Isotretinoin vs. Doxycycline for Acneiform Rash in Patients Receiving Drugs That Target the MAPK Pathway
Started Aug 2026
50 enrolled
Acneiform Drug EruptionAcneiform Eruptions
Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck Cancer
Started Mar 2026
6 enrolled
Head and Neck CancerHead and Neck Small Cell CarcinomaMetastatic Head and Neck Cancer+1 more
Efficacy of Cosmetic Product RV3278B-OS0386 in the Maintenance Phase After Oral Isotretinoin Treatment of Adults Subjects With Facial Acne.
Started Feb 2025
102 enrolled
Acne
Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response.
Started Oct 2023
62 enrolled
Neuroblastoma
Gravitas Feeding Tube System Placement Validation in Neonates
Started Oct 2023
100 enrolled
Nasogastric Tube
Worked on AVITA at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.